GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Organovo Holdings Inc (NAS:ONVO) » Definitions » Pretax Margin %

Organovo Holdings (Organovo Holdings) Pretax Margin % : -72,080.00% (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Organovo Holdings Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Organovo Holdings's Pre-Tax Income for the three months ended in Dec. 2023 was $-3.60 Mil. Organovo Holdings's Revenue for the three months ended in Dec. 2023 was $0.01 Mil. Therefore, Organovo Holdings's pretax margin for the quarter that ended in Dec. 2023 was -72,080.00%.

The historical rank and industry rank for Organovo Holdings's Pretax Margin % or its related term are showing as below:

ONVO' s Pretax Margin % Range Over the Past 10 Years
Min: -7885.54   Med: -908.37   Max: -756.05
Current: -7885.54


ONVO's Pretax Margin % is ranked worse than
89.68% of 1027 companies
in the Biotechnology industry
Industry Median: -176.72 vs ONVO: -7885.54

Organovo Holdings Pretax Margin % Historical Data

The historical data trend for Organovo Holdings's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organovo Holdings Pretax Margin % Chart

Organovo Holdings Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -861.60 -851.91 - -763.07 -4,664.05

Organovo Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,491.60 -4,604.32 -5,368.00 - -72,080.00

Competitive Comparison of Organovo Holdings's Pretax Margin %

For the Biotechnology subindustry, Organovo Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organovo Holdings's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Organovo Holdings's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Organovo Holdings's Pretax Margin % falls into.



Organovo Holdings Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Organovo Holdings's Pretax Margin for the fiscal year that ended in Mar. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Mar. 2023 )/Revenue (A: Mar. 2023 )
=-17.257/0.37
=-4,664.05 %

Organovo Holdings's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-3.604/0.005
=-72,080.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Organovo Holdings  (NAS:ONVO) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Organovo Holdings Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Organovo Holdings's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Organovo Holdings (Organovo Holdings) Business Description

Traded in Other Exchanges
Address
11555 Sorrento Valley road, Suite 100, San Diego, CA, USA, 92121
Organovo Holdings Inc is a biotechnology company, which designs and creates functional and three-dimensional human tissues for medical research and therapeutic applications. It also develops and commercializes a platform technology for the generation of three-dimensional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The company collaborates with pharmaceutical and academic partners to develop human biological disease models in three dimensions. Organovo's key instrument platform is the NovoGen Bioprinter. The firm's 3-D bioprinting technologies create tissues using living cells and biocompatible hydrogels.
Executives
David Gobel director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Vaidehi Joshi director C/O ORGANOVO HOLDINGS, INC., 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Alison Tjosvold Milhous director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Thomas Hess officer: President, CFO and PFO 366 MADISON AVE. 12TH FLOOR, NEW YORK NY 10017
Douglas Jay Cohen director 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Thomas E Jurgensen officer: General Counsel & Secretary 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Jeffrey N. Miner officer: Chief Scientific Officer 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075
Chris Heberlig officer: President and CFO C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Keith Murphy director, officer: Executive Chairman 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Steven George Hughes officer: Chief Medical Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Carolyn Beaver director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
David Shapiro director C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Presnell Sharon Collins officer: EVP, Research & Development 6275 NANCY RIDGE DRIVE, SUITE 110, SAN DIEGO CA 92121
Taylor Crouch director, officer: CEO & President 440 STEVENS AVENUE, SUITE 200, SOLANA BEACH CA 92075

Organovo Holdings (Organovo Holdings) Headlines

From GuruFocus

Organovo Announces One-for-Twenty Reverse Stock Split

By Marketwired Marketwired 08-17-2020

Catherine Wood's ARK Investment Slashes Organovo Holding

By Graham Griffin Graham Griffin 03-11-2021

Organovo Achieves 3D Tissue Model for Crohn's Disease

By GuruFocusNews GuruFocusNews 05-27-2022

Organovo Achieves 3D Tissue Model for Crohn's Disease

By GuruFocusNews GuruFocusNews 07-06-2022

Organovo Achieves 3D Tissue Model for Crohn's Disease

By GuruFocusNews GuruFocusNews 06-06-2022